Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy

N. Masera,C. Rescaldani,M. Azzolini,C. Vimercati,L. Tavecchia,G. Masera,V. De Molfetta,P. Arpa
DOI: https://doi.org/10.3324/haematol.11782
2008-01-01
Haematologica
Abstract:About the 11–14% of patients with thalassemia major (TM) treated with deferasirox (DFO) develops retinopathy and/or lens opacities with an unclear pathogenesis but with a clear age related pattern.[1][1],[2][2] Possible causes can be either iron overload itself or DFO toxicity, with various
What problem does this paper attempt to address?